香港股市 已收市

我們一直致力為你帶來更優質的體驗,因此此網頁即將停止服務。如需參閱此網頁的內容,請瀏覽 篩選器,當中提供類似的內容和功能。

探索/

最常從觀察名單移除的股票

最常從觀察名單移除的股票

4.50k 個跟隨者28 個股票代號 追蹤清單由 Yahoo Finance 提供

跟隨此名單即可探索和追蹤最多雅虎財經用戶從觀察名單移除的股票。此名單每天產生一次,而且只列出符合條件的前 30 名股票。

策劃人: Yahoo Finance

跟隨此名單即可探索和追蹤最多雅虎財經用戶從觀察名單移除的股票。此名單每天產生一次,而且只列出符合條件的前 30 名股票。

背景

雅虎財經運用先進的演算法持續觀察和探索全球金融市場的趨勢。我們會以觀察名單的形式向您提供深入分析。

透過雅虎財經篩選器尋找其他致勝投資意見。

這些股票如何加權?

此觀察名單的股票比重相等。

表現

追蹤清單今日股價變化1 個月回報1 年回報總回報
最常從觀察名單移除的股票----
^GSPC+0.00%+1.08%+30.39%+6262.48%

28 個股票代號

代號公司名稱收市價變化% 變化市場時間成交量平均成交量 (3 個月)市值
  • Motley Fool

    3 Dividend Growth Stocks That Have Increased Their Payouts by More Than 90% in 5 Years

    If you're looking for top dividend stocks to buy, you may be tempted to look at which high-yielding stocks are the safest ones to own. The first is that these businesses prioritize dividend growth (which means your recurring income will rise), and the second is that it usually means their operations are also growing and in strong financial shape. Visa (NYSE: V), UnitedHealth Group (NYSE: UNH), and FedEx (NYSE: FDX) have all increased their dividend payments by more than 90% in just five years.

  • Motley Fool

    3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now

    There are plenty of growth stocks trading at obscenely high valuations right now. If you're on the hunt for some deals and are willing to be patient, three overlooked stocks you should consider loading up on right now are AstraZeneca (NASDAQ: AZN), United Parcel Service (NYSE: UPS), and Dollar Tree (NASDAQ: DLTR). Shares of AstraZeneca finished last week just a few dollars away from the stock's 52-week low of $60.47.

  • TipRanks

    AstraZeneca upgraded to Neutral from Sell at UBS

    UBS upgraded AstraZeneca (AZN) to Neutral from Sell with an unchanged price target of 11,300 GBp. The firm cites the stock’s 24% decline over the past three months amid China government investigations and “disappointing” data on Dato-DXd lung potential for the upgrade. While significant China uncertainty, but wholesale loss of AstraZeneca’s franchise seems unlikely, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaki